Hospital
University Hospital
University Hospital was paid $362.91M by Medicaid between Jan 2018 and Dec 2024, across 717 billing codes. Its largest line is 99283, emergency room visit (moderate) — 12% of everything it billed.
33Billing provider infoUNIVERSITY HOSPITAL
NEWARK, NJ 07103
NEWARK, NJ 07103
33aNPI1215998323assigned 03/29/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$362.91M
24GClaims4,711,661
24DCodes billed717
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#1 of 93
Median peer was paid$30.60M
This provider vs. median12×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 552,925 | $48.24M | |
| 2019 | 583,017 | $47.31M | |
| 2020 | 474,235 | $35.54M | |
| 2021 | 658,189 | $52.67M | |
| 2022 | 811,147 | $58.02M | |
| 2023 | 923,552 | $68.15M | |
| 2024incomplete | 708,596 | $52.98M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 96,411 | 85,259 | $42.79M |
| G0378 | Hospital observation service, per hour | 10% | 28,043 | 23,433 | $37.98M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.7% | 68,583 | 62,531 | $35.03M |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 7.0% | 137,143 | 108,458 | $25.22M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.3% | 33,788 | 30,169 | $22.98M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 6.3% | 231,979 | 187,559 | $22.69M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 3.1% | 30,865 | 27,504 | $11.33M |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.9% | 2,808 | 2,715 | $6.98M |
| OP370 | 1.9% | 22,864 | 21,417 | $6.88M | |
| OP279 | 1.8% | 41,461 | 37,533 | $6.47M | |
| OP710 | 1.6% | 23,992 | 22,688 | $5.85M | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 18,346 | 16,896 | $4.21M |
705 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 2,795 | $3.83M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,594 | $2.99M |
| OP259 | <1% | 179,359 | $2.81M | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 7,499 | $2.59M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 13,438 | $2.49M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 61,838 | $2.39M |
| OP270 | <1% | 25,238 | $2.37M | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 31,839 | $2.29M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 2,826 | $2.18M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 13,279 | $2.18M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 3,139 | $2.06M |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 52,689 | $2.00M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 7,815 | $1.94M |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 341 | $1.93M |
| OP272 | <1% | 20,143 | $1.92M | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 27,208 | $1.91M |
| OP278 | <1% | 2,360 | $1.83M | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,378 | $1.82M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 120,764 | $1.77M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,784 | $1.73M |
| 77386 | <1% | 4,921 | $1.59M | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 10,243 | $1.57M |
| 87536 | <1% | 13,475 | $1.40M | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 1,138 | $1.39M |
| A0425 | Ground mileage, per statute mile | <1% | 169,814 | $1.37M |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,880 | $1.24M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 3,746 | $1.23M |
| 59025 | Fetal non-stress test | <1% | 4,684 | $1.21M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 7,751 | $1.19M |
| 80053 | Comprehensive metabolic panel | <1% | 90,012 | $1.07M |
| 71045 | Radiologic examination, chest; single view | <1% | 40,444 | $1.04M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 30,262 | $1.02M |
| 87631 | <1% | 24,105 | $1.01M | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,096 | $996K |
| 93970 | <1% | 3,418 | $970K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 50,290 | $946K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 3,349 | $944K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 30,932 | $931K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 13,988 | $927K |
| 92557 | <1% | 4,908 | $908K | |
| 49083 | <1% | 1,075 | $901K | |
| 73630 | <1% | 12,958 | $886K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 11,178 | $881K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 24,010 | $871K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 7,250 | $821K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 7,991 | $820K |
| 74183 | <1% | 1,420 | $780K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 29,976 | $768K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 163,965 | $767K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 7,816 | $761K |
| A0998 | Ambulance response and treatment, no transport | <1% | 9,137 | $752K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 13,406 | $735K |
| 64493 | <1% | 595 | $735K | |
| 96376 | <1% | 14,075 | $730K | |
| 93975 | <1% | 2,484 | $727K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 22,491 | $722K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 8,102 | $676K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,882 | $670K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 8,475 | $668K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,295 | $662K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 2,915 | $644K |
| 73560 | <1% | 10,211 | $642K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 115,130 | $631K |
| A0433 | Advanced life support, level 2 (als 2) | <1% | 1,356 | $625K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 969 | $615K |
| 31575 | <1% | 1,401 | $603K | |
| 70486 | <1% | 4,194 | $603K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 32,640 | $595K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 34,683 | $571K |
| 36415 | Collection of venous blood by venipuncture | <1% | 269,605 | $558K |
| 86480 | <1% | 12,044 | $556K | |
| 73590 | <1% | 9,057 | $547K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,057 | $540K |
| 86900 | <1% | 30,630 | $539K | |
| 76830 | Ultrasound, transvaginal | <1% | 7,239 | $528K |
| 72141 | <1% | 766 | $526K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 7,596 | $526K |
| 70491 | <1% | 1,547 | $517K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 19,135 | $515K |
| 77336 | <1% | 3,101 | $497K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,720 | $493K |
| 73030 | <1% | 8,131 | $492K | |
| 92587 | <1% | 2,235 | $468K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,068 | $465K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 15,277 | $455K |
| 52000 | <1% | 752 | $450K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 2,690 | $441K |
| 74170 | <1% | 1,137 | $430K | |
| 73110 | <1% | 9,283 | $428K | |
| 80061 | Lipid panel | <1% | 30,567 | $424K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 4,828 | $422K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,142 | $421K |
| 73610 | <1% | 13,139 | $404K | |
| 20610 | <1% | 1,883 | $398K | |
| J3490 | Unclassified drugs | <1% | 20,191 | $392K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 16,685 | $389K |
| 92567 | <1% | 6,502 | $388K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13,590 | $385K |
| 64483 | <1% | 350 | $380K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 11,999 | $380K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,754 | $378K |
| 73090 | <1% | 5,650 | $376K | |
| 86850 | <1% | 30,784 | $376K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 4,023 | $374K |
| 93971 | <1% | 2,412 | $365K | |
| 73070 | <1% | 5,256 | $365K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,016 | $359K |
| 92083 | <1% | 6,075 | $348K | |
| 96417 | <1% | 1,992 | $342K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 6,062 | $341K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 167 | $337K |
| 88142 | <1% | 8,655 | $334K | |
| 86803 | <1% | 18,515 | $333K | |
| 92579 | <1% | 1,778 | $324K | |
| 71250 | <1% | 2,559 | $316K | |
| 84484 | <1% | 48,371 | $315K | |
| 72082 | <1% | 3,629 | $309K | |
| 73120 | <1% | 7,443 | $304K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 1,586 | $302K |
| 86901 | <1% | 30,693 | $287K | |
| A0434 | Specialty care transport (sct) | <1% | 652 | $284K |
| 72100 | <1% | 6,075 | $278K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 452 | $260K |
| 88342 | <1% | 4,008 | $259K | |
| C1769 | Guide wire | <1% | 2,743 | $258K |
| 93922 | <1% | 1,952 | $257K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 172 | $254K |
| 83735 | <1% | 68,130 | $252K | |
| 73700 | <1% | 1,197 | $249K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,353 | $245K |
| 87522 | Neg quan hep c or qual rna | <1% | 2,929 | $241K |
| 96160 | <1% | 16,029 | $240K | |
| 80076 | <1% | 54,851 | $237K | |
| 96415 | <1% | 2,252 | $232K | |
| 85027 | <1% | 51,053 | $231K | |
| 73060 | <1% | 3,580 | $230K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,434 | $228K |
| 77334 | <1% | 560 | $215K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,875 | $206K |
| 86361 | <1% | 10,363 | $202K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 33,399 | $200K |
| 83880 | <1% | 12,662 | $197K | |
| 88307 | <1% | 2,077 | $196K | |
| 76512 | <1% | 2,789 | $196K | |
| 73564 | <1% | 3,948 | $196K | |
| 76536 | <1% | 1,969 | $195K | |
| 92134 | <1% | 6,814 | $192K | |
| 97161 | <1% | 5,922 | $191K | |
| 85730 | <1% | 61,783 | $189K | |
| 92604 | <1% | 1,253 | $187K | |
| 92626 | <1% | 2,472 | $186K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,027 | $185K |
| 73130 | <1% | 4,607 | $184K | |
| Q3014 | Telehealth originating site facility fee | <1% | 24,412 | $180K |
| 84100 | <1% | 61,846 | $178K | |
| 92133 | <1% | 6,171 | $174K | |
| 59050 | <1% | 2,536 | $173K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 131 | $173K |
| 85610 | <1% | 60,873 | $170K | |
| 66982 | <1% | 117 | $170K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 230 | $170K |
| 87340 | <1% | 12,596 | $168K | |
| 73552 | <1% | 5,335 | $167K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,289 | $166K |
| 20680 | <1% | 93 | $166K | |
| 76825 | <1% | 298 | $164K | |
| 70480 | <1% | 1,277 | $152K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 2,576 | $149K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25,438 | $147K |
| 77066 | Tomosynthesis, mammo | <1% | 1,747 | $145K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 20,527 | $144K |
| 77300 | <1% | 396 | $143K | |
| 82728 | <1% | 10,202 | $142K | |
| 11721 | <1% | 4,063 | $140K | |
| 73502 | <1% | 4,572 | $138K | |
| 82948 | <1% | 69,593 | $138K | |
| 84703 | <1% | 44,725 | $137K | |
| 29581 | <1% | 616 | $132K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 4,723 | $131K |
| 84439 | <1% | 15,841 | $131K | |
| 90651 | <1% | 676 | $128K | |
| 76642 | <1% | 1,874 | $128K | |
| 20611 | <1% | 546 | $126K | |
| 90715 | <1% | 6,629 | $126K | |
| 70496 | <1% | 571 | $126K | |
| 83605 | <1% | 16,238 | $125K | |
| 76801 | <1% | 1,497 | $123K | |
| 86003 | <1% | 925 | $122K | |
| J0178 | Injection, aflibercept, 1 mg | <1% | 208 | $120K |
| 11055 | <1% | 1,582 | $118K | |
| OP721 | <1% | 733 | $114K | |
| 77085 | <1% | 2,426 | $113K | |
| 81001 | <1% | 62,432 | $109K | |
| 94010 | <1% | 764 | $109K | |
| 93798 | <1% | 1,205 | $108K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 365 | $108K |
| 43235 | <1% | 91 | $108K | |
| 97802 | <1% | 1,367 | $103K | |
| 88304 | <1% | 3,946 | $101K | |
| 73000 | <1% | 1,303 | $100K | |
| 0002A | <1% | 2,838 | $100K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,421 | $100K |
| 0001A | <1% | 2,974 | $99K | |
| 70498 | <1% | 554 | $99K | |
| 36430 | <1% | 1,381 | $99K | |
| 83690 | <1% | 27,161 | $98K | |
| 73562 | <1% | 2,881 | $98K | |
| 93880 | <1% | 466 | $96K | |
| 87486 | <1% | 3,761 | $95K | |
| 73521 | <1% | 1,745 | $94K | |
| 84702 | <1% | 11,811 | $94K | |
| 87581 | <1% | 3,760 | $93K | |
| 81401 | <1% | 3,147 | $91K | |
| 96367 | <1% | 2,326 | $91K | |
| 87077 | <1% | 10,583 | $90K | |
| 87497 | <1% | 1,378 | $90K | |
| 95816 | <1% | 414 | $89K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 72 | $86K |
| 72110 | <1% | 1,798 | $86K | |
| 77073 | <1% | 2,180 | $86K | |
| 76770 | <1% | 1,091 | $86K | |
| 77417 | <1% | 1,716 | $85K | |
| 97803 | <1% | 1,187 | $85K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,176 | $84K |
| 72131 | <1% | 689 | $83K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 66 | $83K |
| 70543 | <1% | 137 | $83K | |
| 80074 | <1% | 2,377 | $82K | |
| 87186 | <1% | 6,595 | $82K | |
| 93350 | <1% | 177 | $81K | |
| 84145 | <1% | 3,476 | $80K | |
| 72040 | <1% | 2,375 | $80K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 797 | $80K |
| 77065 | Tomosynthesis, mammo | <1% | 962 | $80K |
| OP229 | <1% | 1,564 | $80K | |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 433 | $79K |
| 90750 | <1% | 710 | $79K | |
| J2704 | Injection, propofol, 10 mg | <1% | 11,866 | $79K |
| 84403 | <1% | 2,740 | $79K | |
| 86706 | <1% | 6,991 | $78K | |
| 94727 | <1% | 1,255 | $78K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,972 | $77K |
| 76775 | <1% | 1,012 | $75K | |
| 84153 | <1% | 4,440 | $75K | |
| 82105 | <1% | 6,379 | $74K | |
| 74018 | <1% | 2,492 | $74K | |
| 93926 | <1% | 344 | $73K | |
| 87070 | <1% | 10,467 | $73K | |
| 97165 | <1% | 2,450 | $73K | |
| 92550 | <1% | 1,169 | $73K | |
| 94644 | <1% | 1,715 | $71K | |
| 77072 | <1% | 1,424 | $70K | |
| 73620 | <1% | 718 | $70K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 667 | $70K |
| 88341 | <1% | 830 | $68K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 602 | $68K |
| 86592 | <1% | 26,419 | $67K | |
| 87517 | <1% | 1,701 | $67K | |
| 71271 | <1% | 1,024 | $66K | |
| 11056 | <1% | 954 | $66K | |
| 86787 | <1% | 4,708 | $65K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 617 | $64K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,831 | $64K |
| 30140 | <1% | 64 | $64K | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 1,240 | $63K |
| 94729 | <1% | 1,243 | $63K | |
| 80197 | <1% | 4,194 | $63K | |
| 87081 | <1% | 7,481 | $63K | |
| C1776 | Joint device (implantable) | <1% | 26 | $60K |
| 83970 | <1% | 1,567 | $60K | |
| 77002 | <1% | 1,154 | $60K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,323 | $60K |
| V2632 | Posterior chamber intraocular lens | <1% | 1,091 | $59K |
| 86704 | <1% | 4,813 | $59K | |
| 76870 | <1% | 599 | $58K | |
| 12011 | <1% | 926 | $57K | |
| 82607 | <1% | 4,892 | $57K | |
| 81000 | <1% | 26,779 | $55K | |
| 58300 | <1% | 42 | $54K | |
| 82550 | <1% | 10,719 | $53K | |
| 87040 | <1% | 4,802 | $52K | |
| 87320 | <1% | 985 | $50K | |
| 86762 | <1% | 4,124 | $49K | |
| 92582 | <1% | 243 | $49K | |
| 85007 | <1% | 18,250 | $48K | |
| 86360 | <1% | 971 | $48K | |
| 31231 | <1% | 350 | $47K | |
| 0003A | <1% | 1,506 | $47K | |
| 30520 | <1% | 38 | $47K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 717 | $46K |
| 95819 | <1% | 226 | $46K | |
| 10060 | <1% | 536 | $45K | |
| 94060 | <1% | 220 | $43K | |
| 72052 | <1% | 586 | $42K | |
| 76641 | <1% | 514 | $41K | |
| 82378 | <1% | 1,872 | $39K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 305 | $39K |
| 77062 | <1% | 875 | $39K | |
| 93925 | <1% | 307 | $38K | |
| 86708 | <1% | 2,633 | $38K | |
| 77412 | <1% | 396 | $37K | |
| 82784 | <1% | 1,913 | $37K | |
| 36226 | <1% | 12 | $37K | |
| 84146 | <1% | 1,612 | $37K | |
| 64635 | <1% | 31 | $36K | |
| 88173 | <1% | 805 | $35K | |
| 83550 | <1% | 6,940 | $35K | |
| 87430 | <1% | 4,383 | $35K | |
| 72190 | <1% | 1,052 | $35K | |
| 74178 | <1% | 160 | $34K | |
| 12001 | <1% | 620 | $34K | |
| 83655 | <1% | 9,234 | $34K | |
| 11720 | <1% | 793 | $34K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,616 | $34K |
| 82248 | <1% | 7,190 | $34K | |
| 72170 | <1% | 1,138 | $33K | |
| 83540 | <1% | 7,578 | $33K | |
| OP255 | <1% | 9,215 | $33K | |
| 82570 | <1% | 10,619 | $33K | |
| 83883 | <1% | 906 | $32K | |
| 80299 | <1% | 4,878 | $32K | |
| 82043 | <1% | 7,542 | $32K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 3,256 | $32K |
| 74174 | <1% | 143 | $31K | |
| 82977 | <1% | 5,414 | $31K | |
| 96401 | <1% | 150 | $31K | |
| 83020 | <1% | 3,715 | $31K | |
| 72070 | <1% | 978 | $31K | |
| 86140 | <1% | 13,208 | $30K | |
| 97162 | <1% | 631 | $30K | |
| 78803 | <1% | 158 | $30K | |
| 86923 | <1% | 933 | $29K | |
| D0330 | Panoramic radiographic image | <1% | 2,555 | $29K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 11,545 | $29K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 240 | $29K |
| 81025 | <1% | 8,012 | $29K | |
| 82375 | <1% | 7,535 | $29K | |
| J0571 | Buprenorphine, oral, 1 mg | <1% | 2,893 | $28K |
| 84481 | <1% | 2,932 | $28K | |
| 92250 | <1% | 468 | $28K | |
| 12002 | <1% | 413 | $27K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,702 | $27K |
| 86334 | <1% | 1,207 | $27K | |
| 69210 | <1% | 160 | $27K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 776 | $26K |
| 55700 | <1% | 13 | $26K | |
| 80164 | <1% | 2,826 | $26K | |
| 82746 | <1% | 3,181 | $26K | |
| 83615 | <1% | 5,167 | $26K | |
| 51798 | <1% | 730 | $25K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 3,097 | $25K |
| 82670 | <1% | 974 | $25K | |
| 86710 | <1% | 1,415 | $24K | |
| 62323 | <1% | 109 | $24K | |
| 86870 | <1% | 439 | $24K | |
| 77080 | <1% | 365 | $24K | |
| 81329 | <1% | 381 | $23K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 451 | $23K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 37 | $22K |
| 74230 | <1% | 262 | $22K | |
| 29580 | <1% | 735 | $22K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 786 | $22K |
| C1762 | Connective tissue, human (includes fascia lata) | <1% | 12 | $22K |
| 93308 | <1% | 156 | $21K | |
| 90746 | <1% | 173 | $20K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 26 | $20K |
| 81229 | <1% | 59 | $20K | |
| 96127 | <1% | 1,105 | $19K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 161 | $19K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 227 | $19K |
| 86780 | <1% | 1,708 | $19K | |
| 77061 | <1% | 370 | $19K | |
| 83001 | <1% | 923 | $18K | |
| 80177 | <1% | 2,446 | $18K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 510 | $18K |
| 31237 | <1% | 16 | $18K | |
| 85652 | <1% | 12,721 | $18K | |
| 82950 | <1% | 4,004 | $18K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 103 | $18K |
| 85378 | <1% | 4,026 | $17K | |
| 57454 | <1% | 87 | $17K | |
| 86300 | <1% | 934 | $17K | |
| 86357 | <1% | 347 | $17K | |
| 87205 | <1% | 3,713 | $17K | |
| 82247 | <1% | 4,155 | $17K | |
| 84480 | <1% | 1,104 | $16K | |
| 88108 | <1% | 1,080 | $16K | |
| 82805 | <1% | 1,820 | $16K | |
| 82009 | <1% | 5,058 | $16K | |
| 51702 | <1% | 167 | $16K | |
| 87902 | <1% | 69 | $15K | |
| 83516 | <1% | 1,595 | $15K | |
| 94660 | <1% | 235 | $15K | |
| 0013A | <1% | 513 | $15K | |
| 82747 | <1% | 1,009 | $15K | |
| 88312 | <1% | 148 | $15K | |
| 73565 | <1% | 295 | $14K | |
| 77338 | <1% | 49 | $14K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 10,626 | $14K |
| OP254 | <1% | 101 | $14K | |
| 78306 | <1% | 55 | $14K | |
| 86705 | <1% | 1,737 | $14K | |
| 86038 | <1% | 1,704 | $14K | |
| J2778 | Injection, ranibizumab, 0.1 mg | <1% | 14 | $14K |
| 29125 | <1% | 198 | $14K | |
| 86355 | <1% | 347 | $13K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 141 | $13K |
| 92611 | <1% | 133 | $13K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,129 | $13K |
| 0012A | <1% | 418 | $12K | |
| 0071A | <1% | 311 | $12K | |
| 86359 | <1% | 347 | $12K | |
| 86920 | <1% | 116 | $12K | |
| 85045 | <1% | 2,835 | $12K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 1,733 | $12K |
| J9171 | Injection, docetaxel, 1 mg | <1% | 91 | $12K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 63 | $11K |
| 0072A | <1% | 286 | $11K | |
| 82553 | <1% | 1,572 | $11K | |
| 73522 | <1% | 221 | $11K | |
| 0124A | <1% | 406 | $11K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 14 | $11K |
| 87210 | <1% | 4,145 | $11K | |
| 0031A | <1% | 302 | $10K | |
| 97164 | <1% | 267 | $10K | |
| 86709 | <1% | 1,416 | $10K | |
| 81400 | <1% | 157 | $10K | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 1,044 | $10K |
| 84156 | <1% | 3,905 | $10K | |
| 83002 | <1% | 531 | $10K | |
| 96402 | <1% | 210 | $10K | |
| 64494 | <1% | 79 | $10K | |
| 92588 | <1% | 45 | $10K | |
| J0248 | Injection, remdesivir, 1 mg | <1% | 73 | $10K |
| 64450 | <1% | 15 | $9K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 256 | $9K |
| 82652 | <1% | 403 | $9K | |
| 87338 | <1% | 833 | $9K | |
| 92602 | <1% | 24 | $9K | |
| 86696 | <1% | 715 | $8K | |
| 82140 | <1% | 1,217 | $8K | |
| 92136 | <1% | 276 | $8K | |
| 76981 | <1% | 199 | $8K | |
| 29515 | <1% | 147 | $8K | |
| 0011A | <1% | 409 | $8K | |
| 10005 | <1% | 29 | $8K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 381 | $8K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 221 | $8K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 6,626 | $8K |
| 90473 | <1% | 340 | $8K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,044 | $8K |
| 86695 | <1% | 734 | $8K | |
| 88300 | <1% | 860 | $7K | |
| 84132 | <1% | 8,867 | $7K | |
| 87901 | <1% | 38 | $7K | |
| 78320 | <1% | 26 | $7K | |
| 82150 | <1% | 1,471 | $7K | |
| 64495 | <1% | 58 | $7K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,494 | $7K |
| 97166 | <1% | 135 | $7K | |
| 77301 | <1% | 20 | $7K | |
| 80185 | <1% | 589 | $7K | |
| 88313 | <1% | 241 | $7K | |
| 96368 | <1% | 513 | $7K | |
| 97760 | <1% | 158 | $7K | |
| 11981 | <1% | 92 | $7K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 405 | $6K |
| 84295 | <1% | 8,363 | $6K | |
| 75774 | <1% | 14 | $6K | |
| 94664 | <1% | 213 | $6K | |
| 73200 | <1% | 40 | $6K | |
| 84165 | <1% | 1,211 | $6K | |
| 76942 | <1% | 100 | $6K | |
| J1815 | Injection, insulin, per 5 units | <1% | 4,351 | $6K |
| 84550 | <1% | 2,081 | $6K | |
| 84436 | <1% | 1,287 | $6K | |
| 87102 | <1% | 759 | $6K | |
| 82435 | <1% | 8,330 | $6K | |
| 82565 | <1% | 1,720 | $6K | |
| 90480 | <1% | 196 | $6K | |
| 97116 | <1% | 194 | $6K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 98 | $6K |
| 59841 | <1% | 56 | $6K | |
| 80320 | <1% | 232 | $6K | |
| 95951 | <1% | 15 | $6K | |
| 93990 | <1% | 30 | $6K | |
| 83021 | <1% | 285 | $6K | |
| 93978 | <1% | 25 | $6K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 983 | $5K |
| 85576 | <1% | 236 | $5K | |
| 92556 | <1% | 70 | $5K | |
| 88331 | <1% | 174 | $5K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,940 | $5K |
| 87799 | <1% | 200 | $5K | |
| 71270 | <1% | 86 | $5K | |
| 84520 | <1% | 1,440 | $5K | |
| 12013 | <1% | 90 | $5K | |
| 92610 | <1% | 95 | $5K | |
| 93242 | <1% | 171 | $5K | |
| 0134A | <1% | 235 | $5K | |
| 83010 | <1% | 417 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,068 | $5K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,754 | $4K |
| 87076 | <1% | 578 | $4K | |
| 84207 | <1% | 98 | $4K | |
| 82088 | <1% | 175 | $4K | |
| 86225 | <1% | 272 | $4K | |
| 87075 | <1% | 611 | $4K | |
| 88360 | <1% | 27 | $4K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 533 | $4K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,355 | $4K |
| 77290 | <1% | 15 | $4K | |
| 92555 | <1% | 59 | $4K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 11,660 | $4K |
| 82103 | <1% | 396 | $4K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,808 | $4K |
| 82947 | <1% | 1,427 | $4K | |
| 86304 | <1% | 251 | $4K | |
| 82533 | <1% | 317 | $4K | |
| 93291 | <1% | 242 | $4K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,601 | $4K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 81 | $4K |
| 87106 | <1% | 530 | $4K | |
| 73650 | <1% | 62 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 121 | $3K |
| 92522 | <1% | 43 | $3K | |
| 90686 | <1% | 250 | $3K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 187 | $3K |
| 88311 | <1% | 486 | $3K | |
| 93289 | <1% | 194 | $3K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,885 | $3K |
| 92540 | <1% | 28 | $3K | |
| 86665 | <1% | 68 | $3K | |
| 10022 | <1% | 12 | $3K | |
| 96411 | <1% | 19 | $3K | |
| 29075 | <1% | 34 | $3K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 238 | $3K |
| 89051 | <1% | 706 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,138 | $3K |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 133 | $3K |
| 92523 | <1% | 30 | $3K | |
| OP637 | <1% | 3,132 | $3K | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 24 | $3K |
| 76376 | <1% | 62 | $2K | |
| 76820 | <1% | 26 | $2K | |
| 74150 | <1% | 47 | $2K | |
| 82390 | <1% | 362 | $2K | |
| 72081 | <1% | 48 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,782 | $2K |
| 88262 | <1% | 16 | $2K | |
| 87391 | <1% | 210 | $2K | |
| 76937 | <1% | 27 | $2K | |
| 93288 | <1% | 224 | $2K | |
| 82627 | <1% | 65 | $2K | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 46 | $2K |
| 87116 | <1% | 145 | $2K | |
| 82135 | <1% | 175 | $2K | |
| 84630 | <1% | 117 | $2K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 39 | $2K |
| 77086 | <1% | 68 | $2K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 671 | $2K |
| 96523 | <1% | 49 | $2K | |
| OP250 | <1% | 62 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 618 | $2K |
| 87529 | <1% | 51 | $2K | |
| 0296T | <1% | 54 | $2K | |
| 86735 | <1% | 131 | $2K | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 127 | $2K |
| 93296 | <1% | 146 | $2K | |
| 77370 | <1% | 12 | $2K | |
| 97597 | <1% | 76 | $2K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 16 | $2K |
| 82785 | <1% | 70 | $2K | |
| 87206 | <1% | 125 | $2K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 51 | $2K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 37 | $2K |
| 83498 | <1% | 39 | $2K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 59 | $2K |
| 73701 | <1% | 15 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 871 | $1K |
| 88185 | <1% | 19 | $1K | |
| 86765 | <1% | 132 | $1K | |
| 86376 | <1% | 212 | $1K | |
| 88230 | <1% | 15 | $1K | |
| 87150 | <1% | 16 | $1K | |
| 77280 | <1% | 15 | $1K | |
| 72050 | <1% | 12 | $1K | |
| 92622 | <1% | 12 | $1K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 620 | $1K |
| 86790 | <1% | 12 | $1K | |
| 86644 | <1% | 96 | $1K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,184 | $1K |
| 92504 | <1% | 36 | $1K | |
| L2999 | Lower extremity orthoses, not otherwise specified | <1% | 134 | $1K |
| 86645 | <1% | 97 | $1K | |
| 82172 | <1% | 65 | $1K | |
| 0034A | <1% | 33 | $1K | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 33 | $1K |
| J0290 | Injection, ampicillin sodium, 500 mg | <1% | 92 | $1K |
| 73140 | <1% | 37 | $1K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 408 | $1K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 21 | $1K |
| OP999 | <1% | 30 | $1K | |
| 88172 | <1% | 14 | $937.49 | |
| 90677 | <1% | 37 | $918.75 | |
| 77001 | <1% | 13 | $898.80 | |
| 86800 | <1% | 55 | $876.75 | |
| 88184 | <1% | 19 | $871.87 | |
| 80050 | General health panel | <1% | 21 | $864.18 |
| 73080 | <1% | 26 | $833.93 | |
| 85384 | <1% | 102 | $823.36 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 87 | $818.83 |
| 77014 | <1% | 32 | $812.53 | |
| 76519 | <1% | 14 | $774.23 | |
| 58100 | <1% | 12 | $769.89 | |
| 84300 | <1% | 208 | $736.20 | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 34 | $708.99 |
| OP403 | <1% | 12 | $699.25 | |
| 84425 | <1% | 122 | $695.05 | |
| 86756 | <1% | 57 | $680.52 | |
| 0064A | <1% | 30 | $671.05 | |
| 80156 | <1% | 60 | $662.92 | |
| 86301 | <1% | 44 | $639.10 | |
| 92201 | <1% | 13 | $616.93 | |
| 88302 | <1% | 27 | $596.65 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 16 | $564.49 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 69 | $556.37 |
| 86617 | <1% | 12 | $548.04 | |
| 86777 | <1% | 69 | $546.88 | |
| 90732 | <1% | 13 | $540.86 | |
| 92025 | <1% | 27 | $531.21 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 176 | $529.20 |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 112 | $519.99 |
| 87641 | <1% | 46 | $516.44 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 119 | $514.71 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 166 | $509.67 |
| L8610 | Ocular implant | <1% | 16 | $504.03 |
| 86430 | <1% | 214 | $477.50 | |
| 91200 | <1% | 19 | $469.65 | |
| 96377 | <1% | 18 | $461.98 | |
| 83520 | <1% | 12 | $455.69 | |
| 86580 | <1% | 44 | $449.31 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 334 | $407.21 |
| 87899 | <1% | 41 | $377.61 | |
| 84144 | <1% | 15 | $363.00 | |
| 86336 | <1% | 12 | $350.06 | |
| 84305 | <1% | 44 | $344.82 | |
| 85014 | <1% | 816 | $340.70 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 590 | $320.54 |
| 72128 | <1% | 16 | $315.73 | |
| 87350 | <1% | 57 | $298.31 | |
| 85347 | <1% | 19 | $264.88 | |
| 82962 | <1% | 65 | $253.52 | |
| 29130 | <1% | 15 | $246.80 | |
| 91300 | <1% | 7,008 | $246.05 | |
| 76872 | <1% | 14 | $241.57 | |
| 86701 | <1% | 115 | $234.80 | |
| 83825 | <1% | 24 | $223.80 | |
| 88104 | <1% | 31 | $217.17 | |
| 82951 | <1% | 75 | $190.88 | |
| 86593 | <1% | 57 | $186.64 | |
| J1120 | Injection, acetazolamide sodium, up to 500 mg | <1% | 12 | $172.29 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 203 | $167.34 |
| 85660 | <1% | 63 | $162.78 | |
| D9210 | <1% | 114 | $158.07 | |
| 94645 | <1% | 14 | $155.70 | |
| 84466 | <1% | 29 | $142.38 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 14 | $123.40 |
| 36416 | <1% | 83 | $118.94 | |
| 82274 | <1% | 29 | $114.83 | |
| 86694 | <1% | 12 | $103.75 | |
| 80178 | <1% | 13 | $103.36 | |
| 80183 | <1% | 14 | $87.66 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 17 | $84.21 |
| 87181 | <1% | 26 | $79.14 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 16 | $79.01 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 23 | $78.79 |
| 87176 | <1% | 13 | $71.40 | |
| 91301 | <1% | 1,427 | $70.00 | |
| 81002 | <1% | 48 | $66.65 | |
| 82310 | <1% | 15 | $60.79 | |
| 87449 | <1% | 14 | $59.48 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 19 | $49.98 |
| 82952 | <1% | 24 | $44.04 | |
| 84157 | <1% | 24 | $40.94 | |
| 81050 | <1% | 14 | $35.36 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 191 | $21.12 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 232 | $21.12 |
| G0008 | Administration of influenza virus vaccine | <1% | 71 | $21.11 |
| 87184 | <1% | 12 | $17.94 | |
| 91303 | <1% | 339 | $16.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 17 | $13.89 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 17 | $8.30 |
| 91312 | <1% | 411 | $6.00 | |
| 91307 | <1% | 596 | $5.00 | |
| 91313 | <1% | 235 | $4.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 15 | $1.05 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 15 | $1.05 |
| 91306 | <1% | 30 | $1.00 | |
| 90611 | 0% | 60 | $0.00 | |
| 91308 | 0% | 38 | $0.00 | |
| 90681 | 0% | 21 | $0.00 | |
| OP780 | 0% | 13 | $0.00 | |
| J2002 | Injection, lidocaine hcl in 5% dextrose, 1 mg | 0% | 24 | $0.00 |
| 90697 | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHUCK, JOHN (CFO)
| Provider | Location | Paid |
|---|---|---|
| University Hospital | Newark, NJ | $1.29M |
| University Hospital | Newark, NJ | $383K |
| University Hospital | Newark, NJ | $184K |
| University Hospital | Newark, NJ | $46K |
| University Hospital | Newark, NJ | $11K |
| University Hospital | Newark, NJ | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.